The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
Open accessAbstract
Background: Low-density lipoprotein cholesterol (LDL-C) has been the cornerstone measurement for assessing cardiovascular risk for nearly 20 years. Content: Recent data demonstrate that apolipoprotein B (apo B) is a better measure of circulating LDL particle number (LDL-P) concentration and is a more reliable indicator of risk than LDL-C, and there is growing support for the idea that addition of apo B measurement to the routine lipid panel for assessing and monitoring patients at risk for cardiovascular disease (CVD) would enhance patient management. In this report, we review the studies of apo B and LDL-P reported to date, discuss potential advantages of their measurement over that of LDL-C, and present information related to standardization. Conclusions: In line with recently adopted Canadian guidelines, the addition of apo B represents a logical next step to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) and other guidelines in the US. Considering that it has taken years to educate physicians and patients regarding the use of LDL-C, changing perceptions and practices will not be easy. Thus, it appears prudent to consider using apo B along with LDL-C to assess LDL-related risk for an interim period until the superiority of apo B is generally recognized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoB can be measured in the nonfasting state because even at peak postprandial concentrations, the number of chylomicron-apoB48 particles in healthy individuals is usually < 1% and the number of VLDL-apoB100 particles is < 10% of the number of LDL-apoB100 particles [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is the structural protein for all non-HDL lipoproteins and exists as 2 isoforms: apoB100, the major isoform in VLDL, IDL, LDL, and Lp(a), and apoB48 in chylomicrons and chylomicron remnants [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Taken together with the evidence that apoB can be measured more accurately, more precisely, and more selectively than LDL-C or non-HDL-C,1,29–31”
From Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention (2024) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Measurement of apolipoprotein B (apoB), the major protein component of LDL, or advanced measurement of LDLP (not yet widely available) can also be used to assess the number of LDL particles [10,12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“ApoB can be measured in the nonfasting state because even at peak postprandial concentrations, the number of chylomicron-apoB48 particles in healthy individuals is usually < 1% and the number of VLDL-apoB100 particles is < 10% of the number of LDL-apoB100 particles [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Since each atherogenic particle contains one molecule of apoB, concentrations of apoB are therefore considered to be a direct measure of the total number of lipoproteins causing cardiovascular disease, that is, LDL, remnants, and Lp(a) [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Cholesterol in the Prediction of Atherosclerotic Disease
Kannel, W. B., Castelli, W. P., & Gordon, T. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-90-1-85 · Cited by 1,314
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163
Sharrett, A. R., Ballantyne, C. M., Coady, S., HEISS, G. M., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 942
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744
Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy
Jeyarajah, E. J., Cromwell, W. C., & Otvos, J. D. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.07.006 · Cited by 734
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 716
Research works printed but not linked: 4
- 2003, JAMC, 169, 921
- 2002, Textbook of cardiovascular medicine, 2nd ed, 2
- 2007, Circulation, 116, 3481
- 2001, Clin Chem Lab Med, 39, 426
Cited by
Sorted by citations
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J. P., Dralle, H., Ebeling, P. R., Melmed, S. K., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,500
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C., Hamilton, J. K., HAY, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,273
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659
Self-citationIndian Journal of Public Health Research & Development
Surwade, V. M., Ambedkar, B. S., Rohinee, & Delhi (2019) · Cited by 404
Metadata
- Authors
- Contois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R.
- Affiliations
- Maine Standards Company, Windham, ME
- Mayo Clinic (US)
- National Institutes of Health (US)
- National Institutes of Health, Bethesda, MD
- University of California Davis Medical Center (US)
- Marshfield Clinic (US)
- Berkeley HeartLab Inc, Alameda, CA
- Corresponding author
- Contois, John H
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-01
- Volume
- 55
- Issue
- 3
- Pages
- 407-419
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2107424758
- Cited by
- 326
- References
- 97
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 7 · 2023: 16 · 2022: 12 · 2021: 24 · 2020: 25 · 2019: 16 · 2018: 22 · 2017: 17 · 2016: 14 · 2015: 16 · 2014: 28 · 2013: 25 · 2012: 24
- FWCI
- 29.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein B, LDL particle number, LDL cholesterol, cardiovascular risk, lipid profile, Canadian guidelines, cardiovascular risk assessment
- MeSH terms
- Apolipoproteins B, Cardiovascular Diseases, Humans, Risk Factors, Clinical Chemistry Tests
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
